A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension.

[1]  P. Gosse,et al.  Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial , 2022, The Lancet.

[2]  G. Naccarelli,et al.  A Systematic Review, Meta-Analysis, and Meta Regression of the Sham Controlled Renal Denervation Randomized Controlled Trials. , 2022, Trends in cardiovascular medicine.

[3]  C. Kim,et al.  Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial , 2021, Hypertension Research.

[4]  M. Uder,et al.  Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial , 2021, The Lancet.

[5]  Dong Li,et al.  Clinical efficacy and safety of spironolactone in patients with resistant hypertension , 2020, Medicine.

[6]  P. Katulanda,et al.  The impact of propranolol on nitric oxide and total antioxidant capacity in patients with resistant hypertension—evidence from the APPROPRIATE trial , 2020, BMC Research Notes.

[7]  A. Manolis,et al.  Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue? , 2019, Current Hypertension Reports.

[8]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[9]  N. Brunetti,et al.  Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? , 2018, Vascular health and risk management.

[10]  K. Rahimi,et al.  Resistant hypertension in times of changing definitions and treatment recommendations , 2018, Heart.

[11]  S. Solomon,et al.  Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction , 2018, American journal of hypertension.

[12]  R. Schmieder,et al.  Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV , 2017, Journal of hypertension.

[13]  Jing Xiao,et al.  Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis , 2017, Blood pressure.

[14]  R. Schmieder,et al.  Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension , 2017, Journal of hypertension.

[15]  A. de la Sierra,et al.  Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – a randomized controlled trial , 2016, Journal of hypertension.

[16]  A. Kaltoft,et al.  Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial , 2016, Journal of hypertension.

[17]  J. Václavík,et al.  Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study , 2016, Hypertension.

[18]  Isla Mackenzie,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[19]  G. Schuler,et al.  Randomized Sham-Controlled Trial of Renal Sympathetic Denervation in Mild Resistant Hypertension , 2015, Hypertension.

[20]  M. Böhm,et al.  Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension , 2015, Clinical Research in Cardiology.

[21]  J. Václavík,et al.  Effect of Spironolactone in Resistant Arterial Hypertension , 2014, Medicine.

[22]  Dean Y. Li,et al.  Smooth muscle specific disruption of the endothelin-A receptor in mice reduces arterial pressure, and vascular reactivity and affects vascular development. , 2014, Life sciences.

[23]  Jianghua Chen,et al.  Effects of Spironolactone on Dialysis Patients With Refractory Hypertension: A Randomized Controlled Study , 2014, Journal of clinical hypertension.

[24]  W. Vongpatanasin.  Resistant hypertension: a review of diagnosis and management. , 2014, JAMA.

[25]  B. Egan,et al.  Role of aldosterone blockade in resistant hypertension. , 2014, Seminars in nephrology.

[26]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[27]  L. Tarnow,et al.  Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial , 2013, Journal of hypertension.

[28]  M. Uder,et al.  Vascular and renal hemodynamic changes after renal denervation. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[29]  T. Peppard,et al.  Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension , 2013, Journal of clinical hypertension.

[30]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[31]  V. Somers,et al.  Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea , 2011, Hypertension.

[32]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[33]  C. Tsioufis,et al.  Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous System , 2011, International journal of hypertension.

[34]  O. Taziki,et al.  Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. , 2011, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[35]  P. Sager,et al.  Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial , 2010, Hypertension.

[36]  B. Wiens,et al.  A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[37]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[38]  B. Wiens,et al.  Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study , 2007, Journal of clinical hypertension.

[39]  C. Wiysonge,et al.  How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis , 2006, Journal of hypertension.

[40]  M. Sartori,et al.  Aldosterone and refractory hypertension: a prospective cohort study. , 2006, American journal of hypertension.

[41]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[42]  G. Dibona.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[43]  A. A. da Silva,et al.  Role of Endothelin-1 in Blood Pressure Regulation in a Rat Model of Visceral Obesity and Hypertension , 2004, Hypertension.

[44]  P. Gillam,et al.  Use of Propranolol (Inderal) in Treatment of Hypertension , 1964, British medical journal.